Genome-wide genotyping
GeneticWhole blood from the participants was used to extract DNA for genotyping.
NCT Number: NCT06801977
This retrospective case-control study aims to investigate the genetic mechanisms of primary Pulmonary Lymphoepithelioma-like Carcinoma, identify genetic susceptibility loci associated with its onset, and explore potential pathogenic genes, providing new insights for its etiological research.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Foshan First People's Hospital, Foshan, Guangdong, China
Pulmonary lymphoepithelioma-like carcinoma (pLELC) is a rare non-small cell lung cancer (NSCLC) that histologically resembles nasopharyngeal carcinoma (NPC) and predominantly affects the Asian population. Epstein-Barr virus (EBV) infection is a recognized pathogenic factor, and the regional prevalence of pLELC suggests that genetic susceptibility also plays an important role. However, no genetic studies on pLELC have been conducted, leaving its genetic etiology poorly understood. In this study, genotyping for all the subjects was performed by using Illumina Infinium Global Screening Array. Genome-wide association followed by meta-analysis was performed for pLELC cases and healthy controls. The primary objective of this study is to discover susceptibility genes that explain the genetic mechanisms of pLELC.
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Case:
Inclusion criteria
The subject is pathologically diagnosed with primary pulmonary lymphoepithelioma-like carcinoma.
Exclusion criteria
The subject is diagnosed with metastatic nasopharyngeal carcinoma; The subject has heavy cardiovascular, liver, or kidney disease.
Controls:
Inclusion criteria
The subject is in good physical condition and has a stable level of consciousness;
Exclusion criteria
The subject has prevalent cancer; The subject has heavy cardiovascular, liver, or kidney disease.
Whole blood from the participants was used to extract DNA for genotyping.
Time frame: The enrollment of the participants
pathological diagnosis of Pulmonary Lymphoepithelioma-like Carcinoma
Contact information is provided by the study sponsor or research team.
Tong-Min Wang, PhD
CONTACT
86+020-87342410
Wei-Hua Jia, MD
CONTACT
86+020-87342327
Sun Yat-sen University
Other
Genetic Susceptibility Study of Primary Pulmonary Lymphoepithelioma-like Carcinoma
Acronym: CPLCC
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.